Sign In
Buy REGN
$618.95
+16.03 (+2.66%)
At Close: Jun 03, 2026
CRISPR Stocks: Will Concerns Over Risk Inhibit Gene-Editing Cures?
10:14am, Thursday, 20'th Oct 2022
Despite CRISPR stocks' enthusiasm, the risk of potential cures continues to cloud market projections for new gene-editing treatments moving through the pipeline toward FDA approval. The post CRISPR St
Roche (RHHBY) Q3 Revenues Dip on Lower COVID-19-Related Sales
05:20pm, Tuesday, 18'th Oct 2022 Zacks Investment Research
Roche's (RHHBY) performance in the third quarter was pretty ho-hum as COVID-19-related sales continue to decline.
2 Biotech Stocks You Can Buy and Hold for the Next Decade
01:53pm, Tuesday, 18'th Oct 2022 The Motley Fool
These two durable companies can navigate the market downturn and beyond.
Is Goldman Sachs Equal Weight U.S. Large Cap Equity ETF (GSEW) a Strong ETF Right Now?
10:20am, Tuesday, 18'th Oct 2022 Zacks Investment Research
Smart Beta ETF report for GSEW
Regeneron (REGN) Stock Sinks As Market Gains: What You Should Know
10:15pm, Monday, 17'th Oct 2022 Zacks Investment Research
Regeneron (REGN) closed the most recent trading day at $735.96, moving -0.01% from the previous trading session.
Analyst Ratings for Regeneron Pharmaceuticals
06:32pm, Monday, 17'th Oct 2022 Benzinga
Regeneron Pharmaceuticals (NASDAQ:REGN) has observed the following analyst ratings within the last quarter:
Bullish
Somewhat Bullish
Indifferent
Somewhat Bearish
Bearish
Total Ratings
2
5
6
0
Regeneron (REGN) Drug Gets Positive CHMP View for Cervical Cancer
05:36pm, Monday, 17'th Oct 2022 Zacks Investment Research
Regeneron (REGN) gets a positive recommendation from CHMP for the label expansion of its oncology drug for treating adult patients with recurrent or metastatic cervical cancer.
Regeneron (REGN) Drug Gets Positive CHMP View for Cervical Cancer
03:03pm, Monday, 17'th Oct 2022
Regeneron (REGN) gets a positive recommendation from CHMP for the label expansion of its oncology drug for treating adult patients with recurrent or metastatic cervical cancer.
Benzinga's Top Ratings Upgrades, Downgrades For October 17, 2022
02:02pm, Monday, 17'th Oct 2022 Benzinga
Upgrades
For Citi Trends Inc (NASDAQ:CTRN), Gordon Haskett upgraded the previous rating of Reduce to Hold. For the second quarter, Citi Trends had an EPS of $0.31, compared to year-ago quarter EPS of
13 Analysts Have This to Say About Regeneron Pharmaceuticals
01:13pm, Monday, 17'th Oct 2022 Benzinga
Over the past 3 months, 13 analysts have published their opinion on Regeneron Pharmaceuticals (NASDAQ:REGN) stock. These analysts are typically employed by large Wall Street banks and tasked with unde
Biotech Stock Sitting Out Today's Rally
10:27am, Monday, 17'th Oct 2022
While the rest of the market is making moves higher today, Regeneron Pharmaceuticals Inc (NASDAQ:REGN) is static, last seen off 0.1% at $735.31.
Why Cash Rich Companies, ETFs are Beating the Market
07:45pm, Friday, 14'th Oct 2022 Zacks Investment Research
We discuss Cash Cows & Trendpilot ETFs.
Regeneron's (REGN) Eylea sBLA Gets FDA's Priority Review
04:56pm, Thursday, 13'th Oct 2022 Zacks Investment Research
The FDA accepts and grants priority review to Regeneron's (REGN) sBLA for Eylea injection to treat retinopathy of prematurity in preterm infants. A decision is due on Feb 11, 2023.
Regeneron's (REGN) Eylea sBLA Gets FDA's Priority Review
02:18pm, Thursday, 13'th Oct 2022
The FDA accepts and grants priority review to Regeneron's (REGN) sBLA for Eylea injection to treat retinopathy of prematurity in preterm infants. A decision is due on Feb 11, 2023.
3 Red-Hot Stocks That Could Continue to Beat the Market
10:30am, Thursday, 13'th Oct 2022 The Motley Fool
Investors are betting on these companies' revenue growth prospects.
